M&A / Deals J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B BioPharma DiveThe buyout hands J J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.OncologyRead full story pharminent June 8, 2026 (Last updated: June 8, 2026) BioPharma Dive The buyout hands J J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates. Oncology Read full story Post navigation Previous: ADA ’26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ optionNext: Pfizer’s Hympavzi secures FDA expanded indications for haemophilia Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026